Efficiency, Ethics and Cost in Pharmaceutical Research and Manufacturing Matthew Wirtala Spring 2006.

Slides:



Advertisements
Similar presentations
David M. Pollock Medical College of Georgia Discovery-Academia.
Advertisements

Consultative expert working group - proposals Barcelona
Patent-Extender Drugs: Loop-holes in the Law Sandy H. Yoo 4/14/06.
Financial Conflicts of Interest in Medical Research Karen Santoro Deputy Ethics Counselor National Institute of Allergy and Infectious Diseases.
Chapter 24 The Economics of Prescription Drugs Copyright © 2010 by The McGraw-Hill Companies, Inc. All rights reserved.McGraw-Hill/Irwin.
The Medical Innovation Prize Fund S.2210, 110 th U.S. Congress David Reynolds, DrPH Senior Health Policy Advisor Senator Bernie Sanders
Genomics Commercialization Glen Schuler Managing Director, Industry Liaison Office University of Saskatchewan.
International Experience in Pharmaceutical Services for Promoting Access to Medicines: Canada, Cuba, England, Mexico International Seminar on the Challenges.
Big Pharma / THE FACTS New Internationalist 362, November 2003.
Health Economics & Policy 3 rd Edition James W. Henderson Chapter 13 Technology in Medicine.
Eve E. Slater, M.D., F.A.C.C. Assistant Secretary for Health Department of Health and Human Services Fostering Innovation in Medicine and Research 2002.
Medication Use. Discussion Question #1 “Drugs represent one of the classical conundrums of life. We can’t live with them; we can’t live without them.”
SUCCESS FACTORS IN THE PHARMACEUTICAL MARKETPLACE
The Global Pharmaceutical Industry Timothy F Christian, MD, MPA.
Discovery of new medicines through new models of collaboration Simon Ward Professor of Medicinal Chemistry & Director of Translational Drug Discovery Group.
The Pharmaceutical Industry. Industry introduction Opportunity How to get into this industry ?
Drug Pricing in Canada Victoria Brown, Anureet Sohi, Lisa Weger SPHA 511.
Pharmaceuticals: Lecture Outline Introduction 1.Historical Development of Pharmaceuticals 2. Modern Uses & Canadian Health Care 3. Doctors & Pharmaceuticals.
Pharmacology II. The Business of Sick.
Stages of drug development
Pharmaceutical Industry Emerging Opportunities for Mobile Health TechNet Meeting June 2005.
The Role of TNCs and AIDS drugs – “Lives before profits”? L.O.s 1.To define the terms: TNC, Generic, “Big Pharma”, ARVs, HAART, Tiered Pricing. 2.To describe.
What You Want to Know About Generic Drugs Generic Drugs: Safe. Effective. FDA-Approved.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 3 Drug Regulation, Development, Names, and Information.
THINK BIG win the world ▪ ACHIEVE the highest results ▪ MAKE the most of your ideas Benefits of Technology Transfer Versus Company IP Presented by: Michael.
Innovation Economics (Pt. 2): “Push” Mechanisms, Mostly Private-Public Partnerships Private-Public Partnerships Stephen M. Maurer Designing Strategies.
1 Value Assessment of Development-Stage Assets Pharmaceutical Products, Medical Devices, and Related Intellectual Property Frank S. Castellana, M.D., Eng.Sc.D.
The Truth About the Drug Companies Marcia Angell, M.D.
Todd Hamilton District Sales Manager. Innovation  On average it takes scientists, physicians, engineers, and other researchers between 10 and 15 years.
Universal Pharmacare: Solving Canada’s Drug Problem Pharmacare Forum Windsor Public Library, April 26, 2011 Canadian Health Coalition.
Intellectual Property and Its Role in Economic Development
Advertising in the Pharmaceutical Industry
From the Lab to Market Unit 3.04 Understanding Biotechnology research & Development.
HSCI 678 Intro to US Healthcare System Biomedical Research, Technology, and Assessment Chapter 10 Dr. Tracey Lynn Koehlmoos.
Drug Delivery and Generic Medicine The Challenge ahead; Choose where to play. MENA as an Industry Model Mohammad Refaat Khattab Cairo University; Egypt.
Controlling Drug Prices: What Canada Does
OUTLINE OF HEALTH CARE PLAN RICHARD R. SCHNEIDER, MD F.A.C.P., F.A.C.C.
An Alternative to Pharmaceutical Patents Christian Engström Vice Chairman, The Swedish Pirate Party.
Managing Risk Through Pharmaceutical Product Life Cycles Hosted and Sponsored by Novartis Institutes for Biomedical Research for HBA Boston Chapter February.
Sucampo Pharmaceuticals, INC.. Overview Background: Sucampo is a pharmaceutical company focused on the development and commercialization of medicines.
Strictly confidential How to achieve sustainability in rapidly changing environment? Pavle Marjanović, Country Manager for Actavis Republic of Serbia and.
HSC 6636: Pharmaceuticals & Medical Technology 1 Dr. Lawrence West, Health Management and Informatics Department, University of Central Florida
Pharmaceuticals – a recap Discuss the view that “drugs companies are not fully addressing the needs of the world’s poorest people.”
DRUG DEVELOPMENT. the roots of Western medicine lie in Ancient Greece: disease and healing were seen in a supernatural context –Healing and religion.
Biotechnology Chemical Pharmaceutical Customer Partnership
The Role of Patents, Universities, and Non-Profits in the Promotion of Health Care Access Nina Gandhi.
McGraw-Hill/Irwin © 2002 The McGraw-Hill Companies, Inc., All Rights Reserved. Chapter 23 The Economics of Prescription Drugs.
Growth in prescription spending had slowed, but increased rapidly in 2014 and 2015 Average annual growth rate of prescription drug spending per capita.
ARRRR! Drug Development and Discovery Access to Essential Medicines De-Cal Fall Week 2.
1 PRIORITY MEDICINES FOR EUROPE AND THE WORLD Barriers to Pharmaceutical Innovation Richard Laing EDM/PAR WHO.
New drug approvals vs.Pharmaceutical R&D expenditures New drug approvals (dots), and pharmaceutical R&D expenditures (shaded area), in the United States.
U.S. Licensing Regulation as a Model for Developing Countries Benton Martin Emory University School of Law Juris Doctor Candidate 2010.
Peterson-Kaiser Health System Tracker What are the recent and forecasted trends in prescription drug spending?
GB590 Corporate Social Responsibility Prof. Ray Kalinski By Willette Marchany Rivera December 13, 2010.
© 2016 Global Market Insights, Inc. USA. All Rights Reserved Fuel Cell Market size worth $25.5bn by 2024 Clinical Trial Management System.
The Physicians Proposal for a National Pharmaceutical Program
Research & development
Free Trade and Intellectual Property Rights: Implications for the Canadian Pharmaceutical Environment Joel Lexchin MD School of Health Policy & Management.
The Economics of Prescription Drugs
The Economics of Prescription Drugs
A journey through drug discovery The life cycle of a new medicine
Biotechnology Chemical Pharmaceutical Customer Partnership
An Increasing Demand for Prescription Drugs Drives Profitability
Prescription for Pharmaceutical Reform: Healing an Ailing System
Introduction to Basic Research Methods
Pharmaceuticals Industry
Public opinion on prescription drugs and their prices
Public opinion on prescription drugs and their prices
Expert Speak: How Pharma Companies Can Grow Their Business?
Global Specialty Pharmaceuticals Market. Report Description and Highlights According to Renub Research report "Specialty Pharmaceuticals Market, by Country.
Presentation transcript:

Efficiency, Ethics and Cost in Pharmaceutical Research and Manufacturing Matthew Wirtala Spring 2006

Overview Background Research & Development Manufacturing Advertising and Marketing

Background: Big Pharma in Philadelphia Manufacturing of medicines shifted from small to large scale Robert Shoemaker is credited as the first large- scale producer (glycerin) 1906: Federal Food and Drugs Act Led to FDA as we know it today

Background: Big Pharma 1950s Rapid innovation and growth Major discoveries Antacids, antidepressants, antihistamines, blood pressure medication 1980 Bayh - Dole Act (1980) Hatch - Waxman Act (1984)

Background: 1980s Legislation Bayh-Dole Act Allowed universities and small businesses to take ownership of inventions discovered with federal funding Permitted licensing for transfer of tech to market Hatch-Waxman Act, etc. Eased transition of generic drugs to market Extended patents on some name brand drugs

Background: Prescription Prices 40% of Americans take at least 1 prescription drug 17% take 3 or more In 1980, average cost per prescription was $52/year Currently $504/year Cheaper in Europe and Canada

Research and Development Disease Research (Target Identification) Preclinical Drug Development Clinical

Research and Development: Clinical Clinical Trials Phase II Phase IPhase III

Research & Development: Costs

R & D: Controversies Where are the truly innovative drugs? “Me-too” drugs for patent extensions Only ~30% of new drugs approved by FDA are NMEs Drastic “black-box” increase in costs Where is the money truly going? Why does the pharma industry remain so profitable (4th most profitable in U.S.)?

Manufacturing Most pharmaceutical manufacturing is done via batch processes Quality assurance through sampling and lab testing Little innovation over past several decades Manufacturing costs ~ $112 billion Averages about 35% of revenue in US

PAT: Process Analytical Technology Part of FDA’s “Good Manufacturing Processes for the 21st Century” initiative Data analysis Improved analysis methods = better understanding of variables involved Process analytical tools Many techniques are out of date

PAT continued Process monitoring Helps to develop better understanding of mechanisms at work in production Better control of key variables involved Continuous feedback Quicker response to variation yields higher quality and reduced production costs Manufacturing savings of 15-50%

Marketing & Advertising The industry spent $19 billion on marketing in % of revenues 30% markup in cost to consumer? Major types of marketing and advertising DTCA Marketing to Doctors

Marketing & Advertising DTCA is illegal in other developed countries (except New Zealand) DTCA: Does it help or hurt? People do go to doctors with symptoms highlighted in advertisements Costs of DTCA were only $3.2 billion (12.5% of all promotions) in 2003 However, that is a 246% increase from 1998

Marketing & Advertising Marketing to Doctors $22.4 billion in % increase from 1998 Does it help or hurt? Large expenditure Many doctors are busy, the short meetings can help inform them about new treatments …or are they more like bribes/kickbacks?

Summary No easy answers, many difficult questions Generally agreed: Something’s gotta change R&D: More transparency? More regulations? Manufacturing: Less controversial, still needs a boost Marketing: How much does it help? Questions/Discussion

References Angell, Marcia, M.D. The Truth About the Drug Companies. New York, NY: Random House, 2004 McKinnell, Hank. A Call To Action. New York, NY: McGraw Hill, 2005 Santoro, Michael A. and Thomas M. Gorrie, eds. Ethics and the Pharmaceutical Industry. New York, NY: Cambridge University Press,